Business Context and Reporting Period
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics targeting the transforming growth factor-beta (TGF-β) family of proteins. The company focuses on three primary product candidates: elritercept (KER-050) for myelodysplastic syndromes (MDS) and myelofibrosis; cibotercept (KER-012) for pulmonary arterial hypertension (PAH); and KER-065 for obesity and neuromuscular diseases. This summary covers the quarterly period ended June 30, 2024.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | Q2 2023 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Total Revenue | $37,000 | $0 | $120,000 | $0 |
| Net Loss | $(45,257,000) | $(37,505,000) | $(88,371,000) | $(73,309,000) |
| Net Loss Per Share | $(1.25) | $(1.27) | $(2.46) | $(2.53) |
| Operating Expenses | $(50,476,000) | $(41,337,000) | $(99,042,000) | $(80,206,000) |
| Cash and Cash Equivalents (End of Period) | $405,863,000 (as of June 30, 2024) | |||
| Accumulated Deficit | $(469,797,000) (as of June 30, 2024) |
Note: All figures in thousands except per share data.
Material Changes vs. Prior Period
- Revenue: The company recognized $37,000 in service revenue in Q2 2024 related to a technology transfer agreement with Hansoh, compared to no revenue in Q2 2023.
- Net Loss: Net loss increased by approximately $7.8 million in Q2 2024 compared to Q2 2023, driven primarily by higher research and development (R&D) expenses.
- R&D Expenses: Q2 2024 R&D expenses were $40.5 million, an increase of $8.0 million from the prior year. This was driven by increased clinical spend for elritercept and cibotercept, and the initiation of the Phase 1 trial for KER-065.
- Liquidity: Cash and cash equivalents increased from $331.1 million at year-end 2023 to $405.9 million at June 30, 2024, bolstered by a $151.1 million public offering in January 2024.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Clinical Milestones: Management expects to report additional data from the elritercept Phase 2 trial in lower-risk MDS and the RESTORE trial (myelofibrosis) in the fourth quarter of 2024. Enrollment for the cibotercept Phase 2 trial (TROPOS) is expected to be completed in Q4 2024. Initial data for KER-065 is expected in Q1 2025.
- Regulatory Alignment: The company received positive feedback from the FDA regarding the design and endpoints for the proposed pivotal Phase 3 trial of elritercept in lower-risk MDS.
- Liquidity Runway: Management believes existing cash resources of $405.9 million are sufficient to fund operations for at least the next 12 months, potentially into 2027.
Risks and Contingencies
- Capital Needs: The company has incurred net losses since inception and expects to continue doing so. Future funding is required to complete development and commercialization.
- Clinical Uncertainty: All product candidates are in clinical development. Failure to demonstrate safety and efficacy in ongoing trials would materially harm the business.
- Third-Party Reliance: The company relies on third parties for manufacturing and clinical trial execution, creating risks related to supply chain and data integrity.
- Intellectual Property: Success depends on protecting proprietary rights and avoiding infringement claims.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $405.9 million cash balance against the projected $84.4 million operating cash outflow for the first half of 2024.
- Clinical Trial Timelines: Monitor the Q4 2024 data readouts for elritercept and cibotercept, as these are critical value drivers.
- Regulatory Status: Confirm the final design of the pivotal Phase 3 trial for elritercept in MDS following FDA feedback.
- Capital Markets: Assess the remaining capacity under the "at-the-market" (ATM) offering program ($349.4 million remaining) and the potential for dilution in future fundraising.
- Revenue Recognition: Review the terms of the Hansoh license agreement to understand the timing and probability of future milestone payments.